Prostatic intraepithelial neoplasia in dogs with spontaneous prostate cancer

Waters, David J.; Hayden, D. W.; Bell, Ford W.; Klausner, Jeffrey S.; Qian, Junqi; Bostwick, David G.

doi:10.1002/(sici)1097-0045(19970201)30:2<92::aid-pros4>3.0.co;2-m

Cited by 50 publications

(26 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In dogs, HGPIN showed cytological features identical to the human counterpart, including cell crowding, loss of polarity, and nuclear and nucleolar enlargement (19). Other similar pathological features of HGPIN between human and canine PCa include basal cell disruption, proliferative index, and microvessel density (20). According to the limited published data, only three research groups have reported their pathological studies of HGPIN in totally 610 dogs with various specimens collected in necropsy, biopsy, and surgical incision (20-24).…”

Section: Canine Spontaneous Pcamentioning

confidence: 99%

“…Other similar pathological features of HGPIN between human and canine PCa include basal cell disruption, proliferative index, and microvessel density (20). According to the limited published data, only three research groups have reported their pathological studies of HGPIN in totally 610 dogs with various specimens collected in necropsy, biopsy, and surgical incision (20-24). Taken together, HGPIN was found in 85 out of 610 dogs with an overall mean incidence of 13.9%; 55 out of 151 (33.1%) dogs with prostate carcinoma had synchronous HGPIN (20-24).…”

Section: Canine Spontaneous Pcamentioning

confidence: 99%

“…According to the limited published data, only three research groups have reported their pathological studies of HGPIN in totally 610 dogs with various specimens collected in necropsy, biopsy, and surgical incision (20-24). Taken together, HGPIN was found in 85 out of 610 dogs with an overall mean incidence of 13.9%; 55 out of 151 (33.1%) dogs with prostate carcinoma had synchronous HGPIN (20-24). However, the relationship of HGPIN and the risk of subsequent development of PCa in dogs remains unknown.…”

Section: Canine Spontaneous Pcamentioning

confidence: 99%

See 2 more Smart Citations

Canine prostate models in preclinical studies of minimally invasive interventions: part I, canine prostate anatomy and prostate cancer models

Sun¹,

Báez-Díaz²,

Sánchez‐Margallo³

2017

Transl. Androl. Urol.

View full text Add to dashboard Cite

The high prevalence of prostate cancer (PCa) in elderly men and technical advances in early detection of localized PCa have led to continued efforts to develop new therapeutic options of minimally invasive nature in current urologic oncology community. Increasing newly emerging therapies are undergoing preclinical tests on the technical feasibility, efficacy and safety in animal experiments. The dog is an ideal large animal because of its similar anatomy to human and the capability allowing the use of the same medical devices applied in future clinical trials. Awareness of the local anatomy, microvascular structure, and histological features of the prostate in dogs is essential to experimental design and performance of the tested procedures and techniques. Although dogs with spontaneous PCa may be used in preclinical investigation, the low incidence and pathological features limit its utility. Alternatively, canine orthotopic PCa models have a great potential in preclinical research for this purpose. The goal of this review is to provide detailed anatomic and histological information of the canine prostate, outline the pathological and clinical characteristics of spontaneous PCa in dogs and discuss the current status of canine orthotopic PCa models.

show abstract

Section: Canine Spontaneous Pcamentioning

confidence: 99%

Section: Canine Spontaneous Pcamentioning

confidence: 99%

Section: Canine Spontaneous Pcamentioning

confidence: 99%

See 1 more Smart Citation

Canine prostate models in preclinical studies of minimally invasive interventions: part I, canine prostate anatomy and prostate cancer models

Sun¹,

Báez-Díaz²,

Sánchez‐Margallo³

2017

Transl. Androl. Urol.

View full text Add to dashboard Cite

show abstract

“…The avidin-biotin-complex technique (Vector Laboratories, Burlingame, CA, USA) was used. Monoclonal antibodies were used to determine proliferative index (anti-MIB-1, Vector Laboratories) [21]. Each section was scanned at low power to identify the region with the highest percentage of cells with MIB-1 positive nuclear staining.…”

Section: Methodsmentioning

confidence: 99%

Prostatic Response to Supranutritional Selenium Supplementation: Comparison of the Target Tissue Potency of Selenomethionine vs. Selenium-Yeast on Markers of Prostatic Homeostasis

et al. 2012

View full text Add to dashboard Cite

Prostate cancer is the product of dysregulated homeostasis within the aging prostate. Supplementation with selenium in the form of selenized yeast (Se-yeast) significantly reduced prostate cancer incidence in the Nutritional Prevention of Cancer Trial. Conversely, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed no such cancer-protective advantage using selenomethionine (SeMet). The possibility that SeMet and Se-yeast are not equipotent in promoting homeostasis and cancer risk reduction in the aging prostate has not been adequately investigated; no direct comparison has ever been reported in man or animals. Here, we analyzed data on prostatic responses to SeMet or Se-yeast from a controlled feeding trial of 49 elderly beagle dogs—the only non-human species to frequently develop prostate cancer during aging—randomized to one of five groups: control; low-dose SeMet, low-dose Se-yeast (3 μg/kg); high-dose SeMet, high-dose Se-yeast (6 μg/kg). After seven months of supplementation, we found no significant selenium form-dependent differences in toenail or intraprostatic selenium concentration. Next, we determined whether SeMet or Se-yeast acts with different potency on six markers of prostatic homeostasis that likely contribute to prostate cancer risk reduction—intraprostatic dihydrotestosterone (DHT), testosterone (T), DHT:T, and epithelial cell DNA damage, proliferation, and apoptosis. By analyzing dogs supplemented with SeMet or Se-yeast that achieved equivalent intraprostatic selenium concentration after supplementation, we showed no significant differences in potency of either selenium form on any of the six parameters over three different ranges of target tissue selenium concentration. Our findings, which represent the first direct comparison of SeMet and Se-yeast on a suite of readouts in the aging prostate that reflect flux through multiple gene networks, do not further support the notion that the null results of SELECT are attributable to differences in prostatic consequences achievable through daily supplementation with SeMet, rather than Se-yeast.

show abstract

“…In another collection of 199 apparently healthy prostate glands from military working dogs, however, HGPIN was detected in only 6/199 (3%) specimens. When prostate glands from dogs with prostatic carcinoma were examined, one study reported that 19/29 (66%) had synchronous HGPIN [4] and 18/25 (72%) dogs with prostatic carcinoma in another study had synchronous HGPIN [5]. In the most recent study, however, HGPIN was detected in only 5/76 (7%) prostatic carcinoma specimens [6].…”

Section: Introductionmentioning

confidence: 99%